Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined with Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma
NCT05400902Phase 2Unknown
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in intrahepatic cholangiocarcinoma (ICC). Status: unknown.
02
Drugs
sintilimabbevacizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05400902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400902.